Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for mo… Read more
Verrica Pharmaceuticals Inc (VRCA) - Net Assets
Latest net assets as of September 2025: $-17.04 Million USD
Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has net assets worth $-17.04 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($40.90 Million) and total liabilities ($57.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-17.04 Million |
| % of Total Assets | -41.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -129.89% |
| 10-Year Change | N/A |
| Growth Volatility | 54.54 |
Verrica Pharmaceuticals Inc - Net Assets Trend (2016–2024)
This chart illustrates how Verrica Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Verrica Pharmaceuticals Inc (2016–2024)
The table below shows the annual net assets of Verrica Pharmaceuticals Inc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-9.86 Million | -149.89% |
| 2023-12-31 | $19.76 Million | -50.63% |
| 2022-12-31 | $40.03 Million | +22.78% |
| 2021-12-31 | $32.60 Million | -1.16% |
| 2020-12-31 | $32.99 Million | -49.26% |
| 2019-12-31 | $65.02 Million | -27.30% |
| 2018-12-31 | $89.43 Million | +1370.12% |
| 2017-12-31 | $-7.04 Million | -164.30% |
| 2016-12-31 | $-2.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Verrica Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 30435100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | % |
| Other Components | $297.16 Million | % |
| Total Equity | $-9.86 Million | 100.00% |
Verrica Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sri panwa Hospitality Real Estate Investment Trust
BK:SRIPANWA
|
$20.93 Million |
|
Chengdu PUTIAN Telecommunications Cable Company Limited
F:CUEH
|
$20.94 Million |
|
PJ Electronics Co. Ltd
KQ:006140
|
$20.94 Million |
|
Guyoung Technology Co. Ltd
KQ:053270
|
$20.94 Million |
|
Maniker F & G Co. Ltd
KQ:195500
|
$20.92 Million |
|
Hermès International Société en commandite par actions
BE:HMI
|
$20.92 Million |
|
Vroom, Inc. Common Stock
PINK:VRM
|
$20.91 Million |
|
Jeilin Technology Co., Ltd.
TWO:8102
|
$20.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Verrica Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,763,000 to -9,860,000, a change of -29,623,000 (-149.9%).
- Net loss of 76,579,000 reduced equity.
- New share issuances of 39,637,000 increased equity.
- Other factors increased equity by 7,319,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-76.58 Million | -776.66% |
| Share Issuances | $39.64 Million | +402.0% |
| Other Changes | $7.32 Million | +74.23% |
| Total Change | $- | -149.89% |
Book Value vs Market Value Analysis
This analysis compares Verrica Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-1.04 | $6.31 | x |
| 2017-12-31 | $-2.74 | $6.31 | x |
| 2018-12-31 | $60.99 | $6.31 | x |
| 2019-12-31 | $26.11 | $6.31 | x |
| 2020-12-31 | $13.20 | $6.31 | x |
| 2021-12-31 | $12.06 | $6.31 | x |
| 2022-12-31 | $11.72 | $6.31 | x |
| 2023-12-31 | $4.36 | $6.31 | x |
| 2024-12-31 | $-1.90 | $6.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Verrica Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1012.15%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-79.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.65 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.75 Million |
| 2018 | -23.09% | 0.00% | 0.00x | 1.03x | $-29.59 Million |
| 2019 | -42.99% | 0.00% | 0.00x | 1.05x | $-34.45 Million |
| 2020 | -137.93% | -379.14% | 0.16x | 2.25x | $-48.80 Million |
| 2021 | -107.59% | -292.33% | 0.15x | 2.46x | $-38.34 Million |
| 2022 | -61.17% | -271.11% | 0.20x | 1.12x | $-28.49 Million |
| 2023 | -338.99% | -1307.47% | 0.06x | 4.13x | $-68.97 Million |
| 2024 | 0.00% | -1012.15% | 0.14x | 0.00x | $-75.59 Million |
Industry Comparison
This section compares Verrica Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Verrica Pharmaceuticals Inc (VRCA) | $-17.04 Million | 0.00% | N/A | $20.93 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |